Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 4:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 143 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pneumococcal Infection Clear all
Completed No phase listed Observational Results available

Impact of Prevnar 13 on Ear Infections in Children

NCT01272999
View directory record Official record
Conditions
Acute Otitis Media, Mastoiditis
Interventions
No intervention
Other
Lead sponsor
Pfizer
Industry
Eligibility
0 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
8
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 23, 2023 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.

NCT00743652
View directory record Official record
Conditions
Pneumococcal Disease, 13-valent Pneumococcal Vaccine
Interventions
13-valent Pneumococcal Conjugate Vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 5 Years
Enrollment
373 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
21
States / cities
Akiak, Alaska • Bethel, Alaska • Chefornak, Alaska + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)

NCT03692871
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13™
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
42 Days to 90 Days
Enrollment
2,409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
22
States / cities
Downey, California • Huntington Beach, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 22, 2026, 4:13 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age

NCT07348692
View directory record Official record
Conditions
Pneumococcal Immunization, Healthy Volunteers
Interventions
PCV21 vaccine, 20vPCV licensed vaccine
Biological
Lead sponsor
Sanofi
Industry
Eligibility
42 Days to 89 Days
Enrollment
2,195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
14
States / cities
Fayetteville, Arkansas • Huntington Park, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)

NCT03615482
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114, QIV, Matching Placebo for V114
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
45
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers

NCT00422292
View directory record Official record
Conditions
Meningococcal Meningitis, Measles, Mumps, Rubella, Varicella
Interventions
Meningococcal Polysaccharide Diphtheria Conjugate Vaccine, Measles, Mumps, Rubella and Varicella
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
9 Months to 12 Months
Enrollment
1,664 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
87
States / cities
Tuscaloosa, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 74 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age

NCT03313037
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Multivalent, Prevnar 13, PPSV23, Saline
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
60 Years to 64 Years
Enrollment
444 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
14
States / cities
Anaheim, California • Coral Gables, Florida • DeLand, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 22, 2026, 4:13 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults

NCT07794748
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
PG4 Multivalent Vaccine, 20 Valent Pneumococcal Conjugate Vaccine (20vPnC)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
4,670 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
37
States / cities
Birmingham, Alabama • Lake Forest, California • Walnut Creek, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 22, 2026, 4:13 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants

NCT03550313
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Multivalent, Prevnar 13
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
565 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
48
States / cities
Mobile, Alabama • Harrisburg, Arkansas • Anaheim, California + 34 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2021 · Synced Oct 22, 2026, 4:13 AM EDT
Completed No phase listed Observational Results available

Effect of Prevnar 13 on Ear Infections in Children

NCT01199016
View directory record Official record
Conditions
Otitis Media
Interventions
Tympanocentesis, Nose/throat swab, Observational
Procedure · Biological
Lead sponsor
Pfizer
Industry
Eligibility
6 Months to 30 Months
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
7
States / cities
Penfield, New York • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2017 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pneumonia Vaccine in Aging HIV Positive Individuals

NCT02558751
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
23-valent pneumococcal polysaccharide vaccine, 13-valent pneumococcal conjugate vaccine
Biological
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
50 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Fever After Simultaneous Versus Sequential Vaccination in Young Children

NCT03165981
View directory record Official record
Conditions
Fever After Vaccination, Fever, Febrile Seizure
Interventions
PCV13, DTaP, IIV
Biological
Lead sponsor
Duke University
Other
Eligibility
12 Months to 16 Months
Enrollment
221 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Oakland, California • Atlanta, Georgia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)

NCT00546572
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
13 valent Pneumococcal Conjugate Vaccine, 23vPS
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
70 Years and older
Enrollment
938 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
51
States / cities
Mobile, Alabama • Mesa, Arizona • Fountain Valley, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2011 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Racial Disparities in Pneumococcal Vaccination in Managed Care

NCT00229762
View directory record Official record
Conditions
Pneumococcal Disease Prevention
Interventions
phone call from nurses - informational only
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
7,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2005 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Phase 4 Interventional

Humoral Determinants of Immunity to Pneumococcal Infection

NCT00304382
View directory record Official record
Conditions
Pneumonia, Pneumococcal Infections, Infections, Streptococcus Pneumoniae
Interventions
Prevnar, Pneumovax
Biological
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2017 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age

NCT03642847
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Prevnar 13, multivalent pneumococcal conjugate formulation 1, multivalent pneumococcal conjugate formulation 2
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
4
States / cities
Garden Grove, California • Long Beach, California • Honolulu, Hawaii + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

NCT05412030
View directory record Official record
Conditions
Pneumonia, Bacterial, Pneumococcal Infections, Pneumonia, Pneumococcal
Interventions
AFX3772, Prevnar 13, Prevnar 20
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
42 Days to 90 Days
Enrollment
388 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
48
States / cities
Jonesboro, Arkansas • Gardena, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 22, 2026, 4:13 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants

NCT06720038
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31, 0.5 mL dose of PCV20, 0.5 mL of the High-PFS dose VAX-31
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
42 Days to 89 Days
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
45
States / cities
Jonesboro, Arkansas • Gardena, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Not applicable Interventional

Pneumonia Vaccine Education Intervention Study

NCT06136832
View directory record Official record
Conditions
Pneumonia, Pneumococcal, Vaccine
Interventions
Pneumococcal Vaccine Education
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years to 64 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

9-valent CRM 197 Pneumococcal

NCT00133549
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
Placebo, PNU-IMUNE®23, Nine-valent pneumococcal conjugate (PNCRM9)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
65 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2002
U.S. locations
2
States / cities
Rochester, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 17, 2014 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)

NCT03893448
View directory record Official record
Conditions
Pneumococcal Infections, Pneumococcal Vaccines
Interventions
V114, Prevnar 13™, RotaTeq™, Pentacel™, RECOMBIVAX HB™, VAQTA™, MMR II™, VARIVAX™, HIBERIX™
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
42 Days to 90 Days
Enrollment
1,720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
66
States / cities
Birmingham, Alabama • Dothan, Alabama • Opp, Alabama + 58 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age

NCT00861744
View directory record Official record
Conditions
Rubella, Mumps, Measles, Measles-Mumps-Rubella Vaccine
Interventions
GSK Biological's investigational vaccine 209762, M-M-R® II (Merck and Co), Varivax®, Havrix®, Prevnar®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
1,259 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
45
States / cities
Tuscaloosa, Alabama • Conway, Arkansas • Jonesboro, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2020 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Not applicable Interventional

Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs

NCT00013871
View directory record Official record
Conditions
HIV Infections, Hepatitis B, Measles, Pneumococcal Infections, Pertussis
Interventions
Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Measles-Mumps-Rubella Vaccine (Live), Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Conjugate Vaccine, Heptavalent, Hepatitis B Vaccine (Recombinant)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 18 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
38
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 22, 2026, 4:13 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effectiveness of the Pneumococcal Polysaccharide Vaccine in Military Recruits

NCT02079701
View directory record Official record
Conditions
Pneumonia, Acute Respiratory Disease
Interventions
23-valent pneumococcal vaccine, Placebo
Biological
Lead sponsor
Naval Health Research Center
Federal
Eligibility
Not listed
Enrollment
152,723 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2007
U.S. locations
5
States / cities
San Diego, California • Great Lakes, Illinois • Fort Leonard Wood, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Oct 22, 2026, 4:13 AM EDT